HK Stock Market Move | CSPC PHARMA (01093) rises over 4% again. SYS 6041 gets FDA approval to conduct clinical trials in the US.

CSPC PHARMA (01093) rose by over 4%, reaching 3.87% at the time of writing, at HK$5.64, with a turnover of HK$287 million. In terms of news, CSPC PHARMA announced that the investigational new drug (IND) application for SYS 6041 (antibody-drug conjugate) developed by the group has been approved by the FDA in the United States, allowing for clinical research in the US. The product received approval from the National Medical Products Administration of China in January 2025 to conduct clinical trials in China. SYS6041 is a monoclonal antibody-drug conjugate that can bind to specific receptors on the surface of tumors, enter cells through endocytosis, and release toxins, thereby killing tumor cells. Additionally, CSPC PHARMA announced that the group's oseltamivir phosphate dry suspension (0.36g) has obtained a drug registration certificate issued by the National Medical Products Administration of China, and is considered to have passed the generic drug quality and efficacy consistency evaluation. The approval of this product will further enrich the group's product line in the field of anti-infective therapies.